EGFR and non-small cell lung carcinoma: A few subsets of NSCLC patients harboring epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) rearrangement were known to respond well to the respective molecular targeted drugs with minimum adverse reaction (2).